These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15750002)

  • 1. First-trimester screening: an overview.
    Eiben B; Glaubitz R
    J Histochem Cytochem; 2005 Mar; 53(3):281-3. PubMed ID: 15750002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
    Chen X; Chang Y; Cui HY; Ren CC; Yu BY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down syndrome screening in the first and second trimesters: what do the data show?
    Rosen T; D'Alton ME
    Semin Perinatol; 2005 Dec; 29(6):367-75. PubMed ID: 16533649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of serum markers in first-trimester down syndrome screening.
    Canick JA; Lambert-Messerlian GM; Palomaki GE; Neveux LM; Malone FD; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Saade GR; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
    Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fetal hepatic artery flow assessment in prenatal diagnostics--a review of the literature].
    Lipa M; Samaha RB; Borowski D; Wielgoś M; Wegrzyn P
    Ginekol Pol; 2014 Jul; 85(7):532-5. PubMed ID: 25118506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choosing the best prenatal screening protocol.
    Simpson JL
    N Engl J Med; 2005 Nov; 353(19):2068-70. PubMed ID: 16282182
    [No Abstract]   [Full Text] [Related]  

  • 11. First-trimester stepwise sequential prenatal screening for Down syndrome using NT and maternal age.
    Miron P
    Prenat Diagn; 2011 Sep; 31(9):915-6. PubMed ID: 21706513
    [No Abstract]   [Full Text] [Related]  

  • 12. [First trimester diagnosis of chromosomal defects].
    Nicolaides KH; Wegrzyn P
    Ginekol Pol; 2005 Jan; 76(1):1-8. PubMed ID: 15844559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [OSCAR (one-stop clinic for assessment of fetal risk): our experience with first trimester screening for chromosomal abnormalities].
    Dhaifalah I; Vrbická D; Santavý J
    Ceska Gynekol; 2006 Sep; 71(5):363-9. PubMed ID: 17131919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of One-Stop-Clinic for Risk Assessment of chromosomal abnormalities in the first trimester, evaluating the effectiveness and making it part of our daily practice.
    Dhaifalah I; Dusek L; Santavy J
    Ceska Gynekol; 2011 Sep; 76(4):292-306. PubMed ID: 22026071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for fetal aneuploidies at 11 to 13 weeks.
    Nicolaides KH
    Prenat Diagn; 2011 Jan; 31(1):7-15. PubMed ID: 21210475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-trimester fetal nasal bone length in an ethnic Chinese population.
    Sahota DS; Leung TY; Chan LW; Law LW; Fung TY; Chan OK; Lau TK
    Ultrasound Obstet Gynecol; 2009 Jul; 34(1):33-7. PubMed ID: 19424993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice.
    Stenhouse EJ; Crossley JA; Aitken DA; Brogan K; Cameron AD; Connor JM
    Prenat Diagn; 2004 Oct; 24(10):774-80. PubMed ID: 15503268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for chromosomal abnormalities.
    Kagan KO; Sonek J; Wagner P; Hoopmann M
    Arch Gynecol Obstet; 2017 Oct; 296(4):645-651. PubMed ID: 28702698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional first-trimester ultrasound markers.
    Sonek J; Nicolaides K
    Clin Lab Med; 2010 Sep; 30(3):573-92. PubMed ID: 20638573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.